Quite a few companies have modified their rankings and value targets on shares of Travere Therapeutics (NASDAQ: TVTX) not too long ago:
- 10/1/2024 – Travere Therapeutics had its value goal raised by analysts at Barclays PLC from $14.00 to $18.00. They now have an “chubby” ranking on the inventory.
- 9/30/2024 – Travere Therapeutics had its value goal lowered by analysts at Canaccord Genuity Group Inc. from $23.00 to $22.00. They now have a “purchase” ranking on the inventory.
- 9/27/2024 – Travere Therapeutics had its value goal lowered by analysts at Citigroup Inc. from $23.00 to $19.00. They now have a “purchase” ranking on the inventory.
- 9/27/2024 – Travere Therapeutics had its value goal lowered by analysts at Guggenheim from $25.00 to $23.00. They now have a “purchase” ranking on the inventory.
- 9/27/2024 – Travere Therapeutics had its value goal lowered by analysts at HC Wainwright from $23.00 to $18.00. They now have a “purchase” ranking on the inventory.
- 9/27/2024 – Travere Therapeutics had its value goal lowered by analysts at Financial institution of America Co. from $19.00 to $18.00. They now have a “purchase” ranking on the inventory.
- 9/13/2024 – Travere Therapeutics had its value goal raised by analysts at JPMorgan Chase & Co. from $20.00 to $23.00. They now have an “chubby” ranking on the inventory.
- 9/10/2024 – Travere Therapeutics had its value goal raised by analysts at Canaccord Genuity Group Inc. from $18.00 to $23.00. They now have a “purchase” ranking on the inventory.
- 9/9/2024 – Travere Therapeutics was upgraded by analysts at Guggenheim from a “impartial” ranking to a “purchase” ranking. They now have a $25.00 value goal on the inventory.
- 9/6/2024 – Travere Therapeutics had its value goal raised by analysts at Citigroup Inc. from $14.00 to $23.00. They now have a “purchase” ranking on the inventory.
- 9/6/2024 – Travere Therapeutics had its value goal raised by analysts at Financial institution of America Co. from $18.00 to $19.00. They now have a “purchase” ranking on the inventory.
- 9/6/2024 – Travere Therapeutics had its value goal raised by analysts at HC Wainwright from $20.00 to $23.00. They now have a “purchase” ranking on the inventory.
- 8/13/2024 – Travere Therapeutics had its value goal raised by analysts at JPMorgan Chase & Co. from $19.00 to $20.00. They now have an “chubby” ranking on the inventory.
- 8/5/2024 – Travere Therapeutics had its value goal raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a “purchase” ranking on the inventory.
Travere Therapeutics Buying and selling Up 11.6 %
Shares of TVTX inventory traded up $1.58 on Friday, reaching $15.23. 3,178,803 shares of the corporate’s inventory had been exchanged, in comparison with its common quantity of 1,342,534. The corporate’s fifty day easy shifting common is $10.99 and its 200 day easy shifting common is $8.61. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week excessive of $15.46. The corporate has a present ratio of three.04, a fast ratio of two.99 and a debt-to-equity ratio of 24.96. The inventory has a market capitalization of $1.16 billion, a PE ratio of -7.25 and a beta of 0.73.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) final introduced its quarterly earnings knowledge on Thursday, August 1st. The corporate reported ($0.90) earnings per share for the quarter, lacking analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a destructive internet margin of 82.14% and a destructive return on fairness of 269.18%. The corporate had income of $54.12 million for the quarter, in comparison with the consensus estimate of $49.50 million. As a bunch, analysts forecast that Travere Therapeutics, Inc. will submit -3.95 EPS for the present yr.
Insider Shopping for and Promoting at Travere Therapeutics
In associated information, Director Jeffrey A. Meckler offered 40,000 shares of the enterprise’s inventory in a transaction that occurred on Monday, September thirtieth. The shares had been offered at a mean value of $14.06, for a complete worth of $562,400.00. Following the completion of the transaction, the director now owns 81,000 shares of the corporate’s inventory, valued at $1,138,860. The commerce was a 0.00 % lower of their possession of the inventory. The sale was disclosed in a submitting with the SEC, which is offered at the SEC web site. In different Travere Therapeutics information, Director Jeffrey A. Meckler offered 40,000 shares of the inventory in a transaction dated Monday, September thirtieth. The shares had been offered at a mean value of $14.06, for a complete transaction of $562,400.00. Following the completion of the sale, the director now straight owns 81,000 shares of the corporate’s inventory, valued at roughly $1,138,860. This represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a submitting with the SEC, which might be accessed by means of this hyperlink. Additionally, CEO Eric M. Dube offered 21,125 shares of the enterprise’s inventory in a transaction that occurred on Monday, September ninth. The inventory was offered at a mean value of $11.52, for a complete transaction of $243,360.00. Following the transaction, the chief govt officer now owns 361,975 shares of the corporate’s inventory, valued at roughly $4,169,952. This commerce represents a 0.00 % lower of their place. The disclosure for this sale might be discovered right here. Within the final quarter, insiders have offered 70,707 shares of firm inventory valued at $915,112. Firm insiders personal 3.75% of the corporate’s inventory.
Hedge Funds Weigh In On Travere Therapeutics
A number of hedge funds have not too long ago modified their holdings of TVTX. Assenagon Asset Administration S.A. raised its stake in Travere Therapeutics by 912.5% within the 2nd quarter. Assenagon Asset Administration S.A. now owns 2,214,099 shares of the corporate’s inventory value $18,200,000 after buying an extra 1,995,419 shares over the last quarter. Parkman Healthcare Companions LLC raised its stake in shares of Travere Therapeutics by 76.4% within the fourth quarter. Parkman Healthcare Companions LLC now owns 1,018,812 shares of the corporate’s inventory value $9,159,000 after buying an extra 441,318 shares over the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Travere Therapeutics by 79.2% throughout the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the corporate’s inventory value $1,423,000 after buying an extra 81,611 shares throughout the interval. GSA Capital Companions LLP bought a brand new stake in Travere Therapeutics within the first quarter valued at roughly $452,000. Lastly, Healthcare of Ontario Pension Plan Belief Fund acquired a brand new place in Travere Therapeutics within the 4th quarter value roughly $5,711,000.
Travere Therapeutics, Inc, a biopharmaceutical firm, identifies, develops, and delivers therapies to individuals residing with uncommon kidney and metabolic ailments. Its merchandise embrace FILSPARI (sparsentan), a once-daily, oral treatment designed to focus on two important pathways within the illness development of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the remedy of cystinuria, a uncommon genetic cystine transport dysfunction that causes excessive cystine ranges within the urine and the formation of recurring kidney stones.
Learn Extra
Obtain Information & Scores for Travere Therapeutics Inc Each day – Enter your e mail handle beneath to obtain a concise each day abstract of the newest information and analysts’ rankings for Travere Therapeutics Inc and associated firms with MarketBeat.com’s FREE each day e mail publication.
